UNSPSC 51372125: Hydromorphone hydrochloride

This classification denotes an opiate with the molecular formula C17H19NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L960UP2KRW, chemically known as morphinone, dihydro-, hydrochloride but more generally known as hydromorphone hydrochloride, which bears US NIH Compound Identifier 3648. European Medicines Agency schedules Hydromorphone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02573MIG.

Most nations, for tariff and trade purposes, schedule hydromorphone hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, HYDROMORPHONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Hydromorphone hydrochloride bears US NLM identifiers UMLS ID C0700533 and NCI Concept Code C436. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@H]3[C@H]1C5)O.CL.

UNSPSC 51372125 Hydromorphone hydrochloride is a Commodity code whose recent state and local activity shows substantial divergence from the pharmaceutical ingredient itself. The code's nominal scope — a specific opioid active pharmaceutical ingredient — does not align with the representative opportunities posted under it. Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeks Naloxone and Safe Drug Deactivation Systems — opioid antagonists and harm-reduction equipment, not hydromorphone. The Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) covers generic multi-source pharmaceuticals and over-the-counter products broadly, with no specific reference to hydromorphone in the scope. The Texas Health and Human Services Commission RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) is exploratory market intelligence on direct-to-manufacturer prescription programs with no product-level specificity. These solicitations indicate that state and local procurement offices are tagging this code when sourcing opioid-related products and pharmacy services more broadly, rather than the active ingredient specifically. The issuing bodies include county health departments (Seminole County), state health and human services commissions (Texas HHS), and cooperative purchasing alliances spanning multiple states and local jurisdictions (MMCAP).

The recent activity spans Florida, Texas, and a multi-state cooperative anchored in Minnesota covering Oregon and other participants. No recent opportunities demonstrate specific demand for hydromorphone hydrochloride as a pharmaceutical ingredient or bulk product. The mismatch between the code's chemical-substance scope and the harm-reduction, OTC, and broad-spectrum pharmacy procurement being posted under it suggests limited relevance for vendors supplying the active ingredient itself. Firms pursuing state and local opportunities under this code should recognize that the category's recent posting activity does not reflect sustained demand for hydromorphone specifically, and that the code's actual use by procurement offices may reflect broader pharmaceutical commodity categorization rather than targeted sourcing for this particular substance.